EUVIMEDEUVIMED entdecken
Crossref

COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only)

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1667d ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: COVID-19, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antirheumatic AgentsHumansCOVID-19 Drug TreatmentAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

ActemraCOVID-19Olumiantbaricitinibdexamethasonedosageefficacytocilizumab

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedAntirheumatic Agents

Zitieren

APA

(2023). COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only). The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1667d

Vancouver

COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only). The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1667d

BibTeX
@article{euvimed2023,
  title = {COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only)},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1667d}
}
Kostenlos starten →